Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts.


Journal

Biochimica et biophysica acta. Gene regulatory mechanisms
ISSN: 1876-4320
Titre abrégé: Biochim Biophys Acta Gene Regul Mech
Pays: Netherlands
ID NLM: 101731723

Informations de publication

Date de publication:
06 2019
Historique:
received: 03 01 2019
revised: 26 03 2019
accepted: 11 04 2019
pubmed: 22 4 2019
medline: 16 10 2019
entrez: 22 4 2019
Statut: ppublish

Résumé

Engineered transcription factors (TF) have expanded our ability to modulate gene expression and hold great promise as bio-therapeutics. The first-generation TF, based on Zinc Fingers or Transcription-Activator-like Effectors (TALE), required complex and time-consuming assembly protocols, and were indeed replaced in recent years by the CRISPR activation (CRISPRa) technology. Here, with coagulation F7/F8 gene promoters as models, we exploited a CRISPRa system based on deactivated (d)Cas9, fused with a transcriptional activator (VPR), which is driven to its target by a single guide (sg)RNA. Reporter gene assays in hepatoma cells identified a sgRNA (sgRNA

Identifiants

pubmed: 31005673
pii: S1874-9399(18)30536-4
doi: 10.1016/j.bbagrm.2019.04.002
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Hepatocyte Nuclear Factor 4 0
RNA, Guide 0
Receptors, Immunologic 0
Transcription Factors 0
trophoblastic beta 1-glycoprotein receptor, human 0
F8 protein, human 839MOZ74GK
Factor VII 9001-25-6
Factor VIII 9001-27-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

619-624

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Silvia Pignani (S)

Department of Life Sciences and Biotechnology, University of Ferrara, Italy; Department of Health Sciences, University of Eastern Piedmont Amedeo Avogadro, Novara, Italy.

Federico Zappaterra (F)

Department of Life Sciences and Biotechnology, University of Ferrara, Italy.

Elena Barbon (E)

Department of Life Sciences and Biotechnology, University of Ferrara, Italy; Genethon and INSERM U951, 91000 Evry, France.

Antonia Follenzi (A)

Department of Health Sciences, University of Eastern Piedmont Amedeo Avogadro, Novara, Italy.

Matteo Bovolenta (M)

Department of Life Sciences and Biotechnology, University of Ferrara, Italy; Genethon and INSERM U951, 91000 Evry, France.

Francesco Bernardi (F)

Department of Life Sciences and Biotechnology, University of Ferrara, Italy.

Alessio Branchini (A)

Department of Life Sciences and Biotechnology, University of Ferrara, Italy. Electronic address: brnlss@unife.it.

Mirko Pinotti (M)

Department of Life Sciences and Biotechnology, University of Ferrara, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH